Ultrashort-acting β-blockers lower mortality in patients with septic shock: Study

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2021-06-16T09:00:31+05:30 | Updated On 10 Oct 2023 5:34 PM IST

Japan: The use of ultrashort-acting β-blockers (such as esmolol and landiolol) significantly lowered 28-day mortality in sepsis patients with persistent tachycardia despite initial resuscitation, finds a recent study in the journal Chest.

Historically, the use of β-blockers is relatively contraindicated for a septic shock as they may lead to cardiac suppression. On the other hand, there is an increasing interest in the β-blockers use for the treatment of patients with sepsis with persistent tachycardia despite initial resuscitation.

Osamu Nishida, Fujita Health University School of Medicine, Aichi, Japan, and colleagues, therefore, aimed to determine whether ultrashort-acting β-blockers such as esmolol and landiolol improve mortality in patients with sepsis with persistent tachycardia despite initial resuscitation in a systematic review and meta-analysis

For this purpose, the researchers searched the online databases for randomized controlled trials (RCTs) that compared the mortality of patients with sepsis and septic shock treated with esmolol or landiolol. Seven RCTs with a pooled sample size of 613 patients were included. Of these, six RCTs with 572 patients reported 28-day mortality.

Also Read: Fluid balance status not linked to readmission chances for patients with sepsis:JAMA

Key findings of the study include:

Esmolol or landiolol use in patients with sepsis and septic shock was significantly associated with lower 28-day mortality (risk ratio, 0.68).
Unimportant heterogeneity was observed (I² = 31%).
The absolute risk reduction and number of patients to be treated to prevent one death were 18.2% and 5.5, respectively.

"Our findings show that the use of ultrashort-acting β-blockers such as esmolol and landiolol in patients with sepsis with persistent tachycardia despite initial resuscitation was associated with significantly lower 28-day mortality," concluded the authors.

Also Read: Speech Induced Tachycardia- Rare case reported in NEJM

Reference:

The study titled, "Effect of Ultrashort-Acting β-Blockers on Mortality in Patients With Sepsis With Persistent Tachycardia Despite Initial Resuscitation: A Systematic Review and Meta-analysis of Randomized Controlled Trial," is published in the journal Chest.

DOI: https://journal.chestnet.org/article/S0012-3692(21)00035-0/fulltext

journal Chestsepsisseptic shockUltrashort acting β blockersesmolollandiolol

Source : journal Chest

Medha Baranwal

MSc. Biotechnology

Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751